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Abstract
Over the last few years, large cohorts of patients with distinct brain disorders of neuropsychiatric and
neurological origin have been analyzed for copy number variation. Surprisingly, the same genetic
abnormalities were found in cohorts of patients affected with mental retardation, autism, or
schizophrenia.
Introduction and context
Copy number variation in brain disease
According to recent estimates, 5-12% of our genome is in
a non-diploid state [1-3]. Copy number variation (CNV)
discovery was enabled by the development of array-
based techniques that detect chromosomal abnormal-
ities at a resolution that may exceed that of traditional
karyotyping under a light microscope by orders of
magnitude. Initially, bacterial artificial chromosome
arrays were used with a resolution in the megabase
range but these were gradually replaced by oligonucleo-
tide arrays with a resolution in the 10- to 100-kilobase
range, thus enabling the detection of detailed CNV maps
of the human genome. Broadly speaking, CNVs fall into
two categories: the common ones that occur in a
significant proportion of the general population and
the rare ones that have been detected at a much lower
frequency. The common CNVs are generally assumed to
play an important role in the natural variation between
individuals, including disease susceptibility, whereas the
rare ones may cause disease.
It is well established that CNVs are responsible for at
least 10% of all cases of mental retardation [4],
predominantly defined by an intelligence quotient of
two standard deviations below the mean. Many of the
rare CNVs identified are unique and have been reported
only once. Whether these are pathogenic depends on a
number of factors, including de novo occurrence, size of
the deletion, and gene content. In contrast, recurrent
CNVs are found in multiple unrelated patients, usually
with common clinical manifestations [5]. Recurrent
CNVs are mostly flanked by low copy repeats (LCRs),
referred to as segmental duplications (Figure 1).
Over the past two years, cohorts of patients with
disorders distinct from mental retardation were analyzed
for CNV. Surprisingly, CNVs at specific chromosomal
regions that are involved in mental retardation, includ-
ing 1q21.1, 15q11-13, 16p11.2, 17p12, and 22q11.2,
also appeared to be associated with autism (qualitative
impairments in social interaction and communication)
and schizophrenia (a psychotic disorder involving
impairments in the perception of reality) (Figure 2).
Moreover, the chromosomal regions encompassing the
neurexin 1 (NRXN1) and the contactin-associated
protein-like 2 (CNTNAP2) genes are also implicated in
the three named disorders.
Major recent advances
Copy number variation discovery in autism and
schizophrenia
Deletions of the chromosomal region 1q21.1, between
two breakpoints (bps) defined as 3 and 4, were initially
described with a wide range of pediatric phenotypes,
includingmildtomoderatementaldelayand dysmorphic
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F1000 Biology Reportsfeatures, microcephaly, cardiac abnormalities, and catar-
act [6]. The reciprocal microduplication was found
predominantly in patients who presented with autism
or autistic features [6,7]. At the same time, 1q21.1
bp3-bp4 microdeletions were identified in 0.25% of
patients with schizophrenia but in only 0.02% of controls
[8-11].
The chromosomal 15q11-13 region has a complex
molecular architecture containing five LCR sequences
or breakpoints, and in addition this chromosomalregion
is subject to genomic imprinting. Paternal deletions of
the region between bp2 and bp3 result in Prader-Willi
syndrome whereas maternal deletions of the same region
result in Angelman syndrome [12]. Patients with an
extended bp1-bp3 deletion present with a more severe
form of the disorder and more commonly display
autistic features. Maternal duplications of the bp2-bp3
region cause a clinically variable neurodevelopmental
disorder frequently associated with autism [13]. In fact,
this duplication, found in 1-3% of patients, is the leading
known cause of this disorder. Deletions and occasionally
duplications of the 15q13.3 bp4-bp5 region were found
in patients with a highly variable degree of mental
handicap, frequently including autistic features [14-16].
The same bp4-bp5 deletion was also one of the more
frequently observed CNVs associated with schizophrenia
[9]. The intermediate bp3-bp4 region seems of little
clinical significance.
A 16p11.2 deletion was found initially in monozygotic
twins with mild mental retardation and multiple
congenital anomalies [17]. Subsequently, a strong
association between the same microdeletion as well as
the reciprocal microduplication and autism was reported
[18-21]. The microdeletion is also found occasionally in
controls, but with a 100-fold lower frequency. In
addition, the microdeletion/duplication is a risk factor
for schizophrenia [8,10].
Figure 1. Non-allelic homologous recombination
Schematic representation of the non-allelic homologous recombination process, generating deletions as well as their reciprocal duplications by unequal
alignment of homologous chromosomes. LCR, low copy repeat.
Figure 2. Schematic overview of genetic overlaps between mental
retardation, autism spectrum disorders, and schizophrenia
Copy number variations that cause mental retardation disorders overlap, to
someextent,withthosethatcauseautisticspectrumdisordersandevenwitha
few that cause schizophrenia. CNTNAP2, contactin-associated protein-like 2.
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abnormalities associated with mental retardation, aut-
ism, and schizophrenia. A duplication of chromosome
17p12 is generally associated with Charcot-Marie-Tooth
disease type 1A (CMT1A) but is also occasionally found
in mentally handicapped or autistic populations [7,22].
A deletion of the same chromosomal region increases the
risk for schizophrenia by a factor of 10 [23]. One of the
most frequent microdeletion syndromes, the 22q11.2
deletion, is associated with developmental delay in
nearly 50% of patients. However, the same deletion is
also found in autistic patients as well as in schizophrenic
patients [8,11,24]. The phenotype of the reciprocal
duplication is highly variable [25]. In addition, rearran-
gements involving the NRXN1 gene on chromosome
2p16 and the CNTNAP2 gene on chromosome 7q35
have been found in patients with mental retardation,
autism, or schizophrenia [7,8,10,26-31]. Both genes are
members of the larger neurexin superfamily involved in
cell-cell interactions in the nervous system [32]. In
contrast to the CNVs mentioned above, the deletions in
these cases were highly variable in size.
Future directions
Unexplained clinical heterogeneity
Thus, several CNVs appear to cause a series of clinically
heterogeneous brain disorders, including mental retarda-
tion, autism, and schizophrenia. Penetrance of these
CNVs may vary and in some cases the abnormalities are
inherited from seemingly unaffected carriers. Such inher-
ited CNVs are better seen as risk factors than as a causative
factor per se. For instance, penetrance of the 16p11.2
duplication in schizophrenia is estimated to be 30-50%.
In other words, carriers of this microduplication have an
8- to 24-fold increased risk of becoming affected [33], in
range with that of other genomic aberrations taking away
one copy of 1q21.1, 15q13 bp4-bp5, or NRXN1 [8,9,34].
While this overview focuses on mental retardation,
autism, and schizophrenia, it has to be mentioned that
many of the CNVs discussed above have also been
associated with a broad range of additional phenotypes,
most notably attention deficit hyperactivity disorder,
epilepsy, and different psychiatric disorders, including
bipolar and major depressive disorder. Interestingly, both
the 16p11.2 microdeletion and the 1q21.1 microduplica-
tion are associated with a combination of autism and
relative macrocephaly. An increased head circumference
in infancy has been reported in patients with autism [35],
suggesting a possible relationship between neurodevelop-
mental disorders and brain volume.
Interpretation of the clinical heterogeneity requires a
greater understanding of how the CNVs lead to disease.
For the most part, the disease resulting from a CNV is
presumably due to an underexpression or overexpression
of the genes in the deleted or duplicated region,
respectively. In addition, it is possible that the deletion
unmasks a recessive mutation on the other allele.
However, imprinting, gene interruption, gene fusion,
position, and transvection effects may also play a role in
determiningclinicalheterogeneityanddiseasepenetrance.
In addition, it is possible that environmental variation of
any kind influences the phenotype, but additional genetic
factorscouldalsoplayarole.Thehumangenomeishighly
variant in both CNV content and single-nucleotide
polymorphisms. Otherwise neutral genetic differences
between individuals, in combination with the above-
mentioned CNVs, might determine whether the patient
presents with mental retardation, autism, or schizophre-
nia. The only known example of such modifying genetic
alterations at present is a recurrent 16p12.1 microdeletion
that modifies neurobehavioral phenotypes [36]. The
presence of this microdeletion in addition to a second
pathogenic CNV manifests clinically as mental retarda-
tion. Perhaps the analysis of new cohorts with an even
larger number of samples might help us to identify
additional modifiers unknown as of yet. Alternatively,
studying the CNV in animal models with a much more
controllable genetic background seems attractive [37].
Thus, although some of the genetic origins of neurodeve-
lopmental disorders are now beginning to be understood,
many discoveries need to be made before we will begin to
understand the common pathways leading to each of
these disorders.
Abbreviations
bp, breakpoint; CNTNAP2, contactin-associated protein-
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